HighTower Advisors LLC Trims Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

HighTower Advisors LLC cut its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 31.0% during the third quarter, Holdings Channel reports. The institutional investor owned 34,958 shares of the medical equipment provider’s stock after selling 15,738 shares during the quarter. HighTower Advisors LLC’s holdings in Zimmer Biomet were worth $3,443,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Zimmer Biomet by 0.9% during the second quarter. Vanguard Group Inc. now owns 23,251,295 shares of the medical equipment provider’s stock valued at $2,120,751,000 after purchasing an additional 198,370 shares in the last quarter. Dodge & Cox grew its stake in shares of Zimmer Biomet by 12.9% in the 2nd quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock worth $2,015,510,000 after buying an additional 2,533,009 shares during the last quarter. American Century Companies Inc. increased its position in Zimmer Biomet by 8.7% during the 2nd quarter. American Century Companies Inc. now owns 5,709,370 shares of the medical equipment provider’s stock valued at $520,752,000 after buying an additional 458,903 shares in the last quarter. Geode Capital Management LLC raised its stake in Zimmer Biomet by 1.4% during the second quarter. Geode Capital Management LLC now owns 5,124,776 shares of the medical equipment provider’s stock valued at $465,480,000 after buying an additional 69,485 shares during the last quarter. Finally, Primecap Management Co. CA boosted its holdings in Zimmer Biomet by 0.6% in the second quarter. Primecap Management Co. CA now owns 4,710,830 shares of the medical equipment provider’s stock worth $429,675,000 after acquiring an additional 27,860 shares in the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Trading Up 0.0%

Shares of ZBH stock opened at $99.90 on Thursday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10. The company has a market cap of $19.55 billion, a price-to-earnings ratio of 28.22, a PEG ratio of 2.04 and a beta of 0.62. Zimmer Biomet Holdings, Inc. has a 1 year low of $84.59 and a 1 year high of $114.44. The firm has a fifty day moving average price of $91.13 and a 200-day moving average price of $95.92.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.38 by $0.04. The company had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The firm’s revenue was up 10.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Tuesday, March 31st. Zimmer Biomet’s payout ratio is currently 27.12%.

Analyst Upgrades and Downgrades

ZBH has been the subject of several analyst reports. Robert W. Baird restated a “neutral” rating and set a $100.00 price target (down from $117.00) on shares of Zimmer Biomet in a report on Tuesday, December 16th. Sanford C. Bernstein raised their price objective on shares of Zimmer Biomet from $97.00 to $99.00 and gave the company a “market perform” rating in a research note on Friday, January 9th. Evercore raised shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and lifted their target price for the stock from $94.00 to $120.00 in a report on Monday, January 5th. Citigroup reiterated a “buy” rating on shares of Zimmer Biomet in a report on Wednesday, February 11th. Finally, Royal Bank Of Canada decreased their price objective on shares of Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $106.20.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.